DNAnexus and Twist Bioscience Collaborate to Provide Data Analysis Software for NGS Workflow
13 July 2022 - 10:03PM
Business Wire
Collaboration integrates DNAnexus’ proven
biomedical data analysis platform with Twist’s NGS Methylation
Detection and Unique Molecular Identifier Adapter Systems
DNAnexus, Inc., a leading provider of cloud-based biomedical
data analysis software serving the life sciences community, and
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic
DNA using its silicon platform, today announced a collaboration
aimed at accelerating research and reducing the time to design,
validate, and commercialize new, high-quality, next-generation
sequencing (NGS)-based diagnostic tests. As part of the
collaboration, Twist customers are able to use the integrated
DNAnexus platform with Twist’s NGS Methylation Detection System and
Unique Molecular Identifier (UMI) Adapter System to simplify data
analysis after sequencing.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20220713005049/en/
The Twist NGS Methylation Detection System provides robust
sample preparation and target enrichment solutions for identifying
methylated regions in the human genome. Rare diseases, cancer, and
other disorders can be identified by unique methylation patterns
within samples. The NGS Methylation Detection System uses highly
sensitive hybridization capture-based technology that can be
integrated into diagnostic tests. This workflow can also be used to
better characterize and understand the genetic mechanisms linked to
specific conditions including cancer, neurodegeneration, and rare
diseases. The Twist UMI Adapter System detects low-frequency
variants in low-input sample sources such as cell-free DNA (cfDNA)
and can be used to enable cancer research. The DNAnexus platform
allows users to easily explore and analyze complex datasets in a
single, scalable, cloud-based environment.
“This collaboration with DNAnexus is another example of our
ongoing commitment to providing our customers with the tools they
need for complete, customized, end-to-end workflows,” said Emily M.
Leproust, PhD, CEO and co-founder of Twist Bioscience. “Our
customers can now access industry-leading computational
infrastructure platforms to support their bioinformatics needs and
reduce their data analysis timeline after performing a sequencing
run with our NGS Methylation Detection and UMI Adapter
Systems.”
Today, DNAnexus has more than 12,000 users across 48 countries
and works with the largest and most innovative pharmaceutical
companies, diagnostic laboratories, and academic medical centers
around the world, along with the UK Biobank and the FDA. The
platform provides a comprehensive cloud environment that supports
the entire diagnostic development and production cycle from R&D
through to deployment of the validated test. The environment was
designed to meet the most rigorous standards for quality, security,
privacy, and safety.
“Twist’s proprietary synthetic DNA tools continue to be used to
advance research and precision medicine and to change the way
diagnostics are developed,” said John Ellithorpe, PhD, President of
DNAnexus. “With the integrated DNAnexus platform, Twist customers
can now reduce the complex data analysis bottleneck, which we
believe will offer significant time savings and cost
advantages.”
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture, and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube
About DNAnexus
To improve human health, researchers and clinicians need to
access complex and sensitive biomedical data and innovative
technologies that can enable novel insights. However, these data
are often incompatible or difficult to process. DNAnexus is the
leading bioinformatics company that facilitates secure access and
utilization of biomedical data while supporting collaboration
across internal and external teams. From providing an end-to-end
integrated diagnostic R&D and production bioinformatics
platform that enables national biobank biomedical initiatives to
providing pharmaceutical companies with a multi-omics data science
platform for new target drug discovery, DNAnexus empowers the
healthcare and life sciences industry to transform how they
leverage biomedical data to accelerate scientific discoveries and
deliver better patient care. For more information on DNAnexus,
please visit www.dnanexus.com or follow the company @DNAnexus.
Twist Legal Notice Regarding Forward-Looking
Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein, including but not limited to the ability of the
collaboration to simplify data analysis and accelerate research and
the development and implementation of new diagnostic tests, are
forward-looking statements reflecting the current beliefs and
expectations of management made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements involve known and unknown risks,
uncertainties, and other important factors that may cause Twist
Bioscience’s actual results, performance, or achievements to be
materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. For a description of the risks and uncertainties that
could cause actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to Twist
Bioscience’s business in general, see Twist Bioscience’s risk
factors set forth in Twist Bioscience’s Quarterly Report on Form
10-Q filed with the Securities and Exchange Commission on May 6,
2022 and subsequent filings with the SEC. Any forward-looking
statements contained in this press release speak only as of the
date hereof, and Twist Bioscience specifically disclaims any
obligation to update any forward-looking statement, whether as a
result of new information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220713005049/en/
For DNAnexus: Andrew Noble 415-722-2129 andrew@bioscribe.com
For Twist Bioscience: Angela Bitting 925-202-6211
abitting@twistbioscience.com
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jun 2024 to Jul 2024
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jul 2023 to Jul 2024